Clinical Significance of Gene Amplification Studied in Human Neuroblastoma Xenografts: Relationship with Tumor Growth Rate, Chemotherapeutic Sensitivities and Levels of Neuron-Specific Enolase

Pathobiology ◽  
1988 ◽  
Vol 56 (5) ◽  
pp. 277-284 ◽  
Author(s):  
Yoshiaki Tsuchida ◽  
Naotoshi Kanda ◽  
Hiroyuki Shimatake ◽  
Yasuhiko Kaneko ◽  
Tsugunori Notomi
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Clinical Significance ◽  
Gene Amplification ◽  
Neuron Specific Enolase ◽  
Tumor Growth Rate ◽  
Human Neuroblastoma

scholarly journals Clinical Significance of Pretreatment Tumor Growth Rate for Locally Advanced NSCLC

2017 ◽  
Vol 99 (2) ◽  
pp. E489
Author(s):  
B. Osorio ◽  
C.B. Simone ◽  
C. Hadzitheodorou ◽  
S. Kim ◽  
D.K. Gaines ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Clinical Significance ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Tumor Growth Rate ◽  
Locally Advanced Nsclc

scholarly journals SENSITIVITY OF THE TRANSPLANTED HUMAN NEUROBLASTOMA TO ONCOLYTIC СOXSACKIE A7 VIRUS

2017 ◽  
Vol 22 (3) ◽  
pp. 158-163
Author(s):  
Anastasiia O. Sosnovtceva ◽  
S. Sh Karshieva ◽  
G. B Smirnova ◽  
Yu. A Borisova ◽  
O. V Lebedinskaya ◽  
...  
Keyword(s):  
Growth Rate ◽  
Cancer Research ◽  
Tumor Growth ◽  
Cytolytic Activity ◽  
Research Center ◽  
Tumor Growth Rate ◽  
Male Mice ◽  
Human Neuroblastoma

Oncolytic viral therapy is a promising approach to targeted therapy of malignant tumors. In this article we consider the therapeutic potential of a non-pathogenic Coxsackie A7 virus (CA7V) with neurotropic properties on a model of human neuroblastoma. Purpose to study in vitro/in vivo sensitivity of human neuroblastoma HNB (from cell line JMR-32) to Coxsackie virus A7 (CA7V). Objectives: еvaluation of cytolytic activity in vitro on NB cells verified by cytomorphology and assessment of dynamics of the growth of subcutaneous neuroblastoma xenografts in Balb/c nude male mice exposed to CA7V multiple i.v. injections. Material and methods. CA7V was produced in the cells of line-producer С-33А. Cell culture and the strain of transplanted NB (JMR-32) were obtained from the Collection of N.N. Blokhin Russian Cancer Research Center. Cytomorphologic verification of neuroblastoma and CA7V cytolytic activity were executed with the use of standard cultural methods, TCID50 and IC50 criteria. Experiments «in vivo» were performed on immunodeficient Balb/c nude male mice bred and reared in the N.N. Blokhin Russian Cancer Research Center. The experiments were made at day 6 when neuroblastoma subcutaneous xenografts developed to the Vmean = 79-82 mm3 by day 6. The treatment with CA7V at the i.v. single dose of 1×108 cells per mouse was performed 3 times with 72-hours intervals; evaluation of the efficacy was made according to standard criterion Т/С ≤ 42%; and control of the tumor growth rate (Vt/V0) in the dynamics. Statistical assessment was made with the software Excel for Windows 2007 with the use of T-test under p ≤ 0.05. Results. Cytolytic effect of CA7V on neuroblastoma cells was registered similar to basic parameters of the original line-producer С-33А: TCID50 = 0.99×10-4 pfu/cell, and IC50 = 1.11×10-4 pfu/cell; 48 and 72 hours after virus reproduction in NB cells the rate was 2.0 and 1.5-fold higher than in the line-producer cells. СA7V inhibiting effect on the growth of large subcutaneous neuroblstoma xenografts is registered after the first i.v. injection at the minimal level of T/C = 67% (criterion ≤ 42%) with the 1.5-fold decrease of the tumor growth rate and cancellation of early mice death by day 22 vs day 15 in the control group of untreated mice (n = 8). Conclusion. The obtained results allow to consider human neuroblastoma (JMR-32) to possess the low sensitivity to oncolytic effect of in vitro/in vivo. In order to obtain significant effect in vivo the treatment should be started in mice with 2-fold smaller tumors and a higher initial dose of the oncolytic agent.

scholarly journals Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer

2019 ◽  
Vol 7 (5) ◽  
pp. 95-95
Author(s):  
Benedict Osorio ◽  
Nikhil Yegya-Raman ◽  
Sinae Kim ◽  
Charles B. Simone II ◽  
Christina Theodorou Ross ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Tumor Growth Rate ◽  
Small Cell Lung

scholarly journals Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor

2010 ◽  
Vol 53 (5) ◽  
pp. 1101-1108 ◽  
Author(s):  
Fernando Guimarães ◽  
Alessandra Soares Schanoski ◽  
Tereza Cristina Samico Cavalcanti ◽  
Priscila Bianchi Juliano ◽  
Ana Neuza Viera-Matos ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Wistar Rats ◽  
Tumor Regression ◽  
Growth Characteristics ◽  
Tumor Growth Rate ◽  
Continuous Growth ◽  
Tumor Bearing ◽  
Walker 256 ◽  
Complete Tumor

The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.

Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells

Neurosurgery ◽  
2015 ◽  
Vol 79 (3) ◽  
pp. 481-491 ◽  
Author(s):  
Alexander E. Ropper ◽  
Xiang Zeng ◽  
Hariprakash Haragopal ◽  
Jamie E. Anderson ◽  
Zaid Aljuboori ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Growth Rate ◽  
Neural Stem Cells ◽  
Tumor Growth ◽  
Rat Model ◽  
Weight Bearing ◽  
Tumor Growth Rate ◽  
Intramedullary Spinal Cord ◽  
Human Neural Stem Cells

Abstract BACKGROUND There are currently no satisfactory treatments or experimental models showing autonomic dysfunction for intramedullary spinal cord gliomas (ISCG). OBJECTIVE To develop a rat model of ISCG and investigate whether genetically engineered human neural stem cells (F3.hNSCs) could be developed into effective therapies for ISCG. METHODS Immunodeficient/Rowett Nude rats received C6 implantation of G55 human glioblastoma cells (10K/each). F3.hNSCs engineered to express either cytosine deaminase gene only (i.e., F3.CD) or dual genes of CD and thymidine kinase (i.e., F3.CD-TK) converted benign 5-fluorocytosine and ganciclovir into oncolytic 5-fluorouracil and ganciclovir-triphosphate, respectively. ISCG rats received injection of F3.CD-TK, F3.CD, or F3.CD-TK debris near the tumor epicenter 7 days after G55 seeding, followed with 5-FC (500 mg/kg/5 mL) and ganciclovir administrations (25 mg/kg/1 mL/day × 5/each repeat, intraperitoneal injection). Per humane standards for animals, loss of weight-bearing stepping in the hindlimb was used to determine post-tumor survival. Also evaluated were autonomic functions and tumor growth rate in vivo. RESULTS ISCG rats with F3.CD-TK treatment survived significantly longer (37.5 ± 4.78 days) than those receiving F3.CD (21.5 ± 1.75 days) or F3.CD-TK debris (19.3 ± 0.85 days; n = 4/group; P &lt;.05, median rank test), with significantly improved autonomic function and reduced tumor growth rate. F3.DC-TK cells migrated diffusively into ISCG clusters to mediate oncolytic effect. CONCLUSION Dual gene-engineered human neural stem cell regimen markedly prolonged survival in a rat model that emulates somatomotor and autonomic dysfunctions of human cervical ISCG. F3.CD-TK may provide a novel approach to treating clinical ISCG.

scholarly journals Tumor Growth Rate Determines the Timing of Optimal Chronomodulated Treatment Schedules

2010 ◽  
Vol 6 (3) ◽  
pp. e1000712 ◽  
Author(s):  
Samuel Bernard ◽  
Branka Čajavec Bernard ◽  
Francis Lévi ◽  
Hanspeter Herzel
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Tumor Growth Rate

A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice

2007 ◽  
Vol 66 (5) ◽  
pp. 428
Author(s):  
Fonghsu Kuo ◽  
Timothy Kotyla ◽  
Thomas Wilson ◽  
Lydia Kifle ◽  
Thomai Panagiotou ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Nude Mice ◽  
Tumor Growth Rate ◽  
Anti Oxidant

scholarly journals Performance of Low-dose CT Screening for Detecting Lung Cancer at the Early Stage and the Estimated Tumor Growth Rate According to the Smoking Status/Age

Haigan ◽  
2014 ◽  
Vol 54 (7) ◽  
pp. 937-946
Author(s):  
Shusuke Sone ◽  
Ryoichi Kondo ◽  
Keiko Ishii ◽  
Takayuki Honda ◽  
Kazuo Yoshida ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Low Dose ◽  
Early Stage ◽  
Smoking Status ◽  
Tumor Growth Rate ◽  
Ct Screening ◽  
Low Dose Ct
Sign in / Sign up

Export Citation Format

Share Document